TY - JOUR
T1 - Cannabinoids for sleep disorders
T2 - Weeding through the evidence
AU - Walsh, Jennifer H.
AU - Eastwood, Peter R.
PY - 2020/10
Y1 - 2020/10
N2 - Sleep disorders are common and include obstructive sleep apnoea (OSA), insomnia, parasomnias, movement disorders and neurological disorders such as narcolepsy. Consequences of untreated sleep disorders include cardiovascular disease, metabolic dysfunction, cognitive impairment and depression. The financial burden of sleep disorders is also significant with the total annual cost of undiagnosed OSA in the US alone estimated to be in excess of US$149b in 2015 [1]. It is estimated that US$100b per year would be saved if every adult with OSA in the US were diagnosed and treated.
AB - Sleep disorders are common and include obstructive sleep apnoea (OSA), insomnia, parasomnias, movement disorders and neurological disorders such as narcolepsy. Consequences of untreated sleep disorders include cardiovascular disease, metabolic dysfunction, cognitive impairment and depression. The financial burden of sleep disorders is also significant with the total annual cost of undiagnosed OSA in the US alone estimated to be in excess of US$149b in 2015 [1]. It is estimated that US$100b per year would be saved if every adult with OSA in the US were diagnosed and treated.
KW - apnoea
KW - insomnia
KW - parasomnias
KW - Sleep disorders
KW - Cannabinoids
UR - http://www.scopus.com/inward/record.url?scp=85089187041&partnerID=8YFLogxK
UR - http://purl.org/au-research/grants/NHMRC/1136548
U2 - 10.1016/j.smrv.2020.101363
DO - 10.1016/j.smrv.2020.101363
M3 - Editorial
C2 - 32781403
AN - SCOPUS:85089187041
VL - 53
JO - Sleep Medicine Reviews
JF - Sleep Medicine Reviews
SN - 1087-0792
M1 - 101363
ER -